{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:23:43Z","timestamp":1788715423143,"version":"build-2803163510"},"reference-count":55,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe community-acquired pneumonia (SCAP) is difficult to treat when caused by difficult-to-treat (DTR) pathogens because of limited treatment options and poorer clinical outcomes. Over time, several predictive scoring systems based on risk factors for infection with multidrug resistant pathogens have been developed. We reviewed the available tools for identifying DTR pathogens as the cause of SCAP, both predictive scoring systems and rapid diagnostic methods, to develop management strategies aimed at early identification of DTR pathogens, reducing broad-spectrum antibiotic use and improving clinical outcomes. The scoring systems reviewed show considerable heterogeneity among them at the level of the region studied, the definition of risk factors, as well as which DTR pathogens are the target pathogens. The models described have shown limited effectiveness in reducing inappropriate antibiotic treatment or improving patient outcomes by themselves. However, predictive models could serve as a first step in identifying DTR pathogen infections as part of a larger detection algorithm. Rapid diagnostic tools, such as multiplex polymerase chain reaction, would be useful for the rapid identification of pneumonia-causing pathogens and their resistance mechanisms. In resource-limited settings, rapid tests should be limited to patients at high risk of developing SCAP due to DTR pathogens. We propose an integrative algorithm based on the different scores, taking into account local epidemiological data, where ideally each center should have an antimicrobial stewardship program.<\/jats:p>","DOI":"10.1055\/s-0043-1778138","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:47:01Z","timestamp":1706831221000},"page":"246-254","source":"Crossref","is-referenced-by-count":1,"title":["Risk of Multidrug-Resistant Pathogens in Severe Community-Acquired Pneumonia"],"prefix":"10.1055","volume":"45","author":[{"given":"E.","family":"Campa\u00f1a-Duel","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Camprub\u00ed-Rimblas","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Areny-Balaguer\u00f3","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Quero","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Artigas","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ceccato","sequence":"additional","affiliation":[{"name":"Critical Care Center, Parc Taul\u00ed Hospital Universitari, Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA), Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain"},{"name":"Centro de Investigaci\u00f3n Biomedica En Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Barcelona, Spain"},{"name":"Intensive Care Unit, Hospital Universitari Sagrat Cor, Grupo Quironsalud, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"S Aliberti","year":"2021","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"C J Murray","year":"2022","journal-title":"Lancet"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"S Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"e0191721","DOI":"10.1371\/journal.pone.0191721","article-title":"Severe community-acquired pneumonia: characteristics and prognostic factors in ventilated and non-ventilated patients","volume":"13","author":"M Ferrer","year":"2018","journal-title":"PLoS One"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/thx.2010.143982","article-title":"Microbial aetiology of community-acquired pneumonia and its relation to severity","volume":"66","author":"C Cill\u00f3niz","year":"2011","journal-title":"Thorax"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archinternmed.2009.259","article-title":"Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules","volume":"169","author":"C McCabe","year":"2009","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"1900057","DOI":"10.1183\/13993003.00057-2019","article-title":"Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study","volume":"54","author":"B J Webb","year":"2019","journal-title":"Eur Respir J"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","article-title":"Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia","volume":"180","author":"B E Jones","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cir840","article-title":"Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia","volume":"54","author":"S Aliberti","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"1701190","DOI":"10.1183\/13993003.01190-2017","article-title":"Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients","volume":"52","author":"M I Restrepo","year":"2018","journal-title":"Eur Respir J"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/resp.13663","article-title":"Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia","volume":"25","author":"D Villafuerte","year":"2020","journal-title":"Respirology"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes","volume":"63","author":"W H Self","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1128\/AAC.02582-14","article-title":"Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia","volume":"58","author":"A E Gross","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"09","key":"ref14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/qjmed\/hct152","article-title":"Risk factors for drug-resistant bacterial pneumonia in older patients hospitalized with pneumonia in a Chinese population","volume":"106","author":"H M Ma","year":"2013","journal-title":"QJM"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/resp.12651","article-title":"Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia","volume":"21","author":"M L Metersky","year":"2016","journal-title":"Respirology"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1471-2334-13-268","article-title":"A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia","volume":"13","author":"A F Shorr","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications","volume":"67","author":"D M Parente","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An Official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"J P Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/QCO.0b013e32835023fb","article-title":"Is healthcare-associated pneumonia a distinct entity needing specific therapy?","volume":"25","author":"S Ewig","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"e0119528","DOI":"10.1371\/journal.pone.0119528","article-title":"Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia","volume":"10","author":"M Falcone","year":"2015","journal-title":"PLoS One"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"A C Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"20","key":"ref23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1001\/archinte.168.20.2205","article-title":"Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia","volume":"168","author":"A F Shorr","year":"2008","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/cir813","article-title":"Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department","volume":"54","author":"A F Shorr","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/thoraxjnl-2013-203384","article-title":"Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective","volume":"68","author":"S Aliberti","year":"2013","journal-title":"Thorax"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Y Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/acem.12672","article-title":"Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia","volume":"22","author":"W H Self","year":"2015","journal-title":"Acad Emerg Med"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia","volume":"12","author":"E Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1513\/AnnalsATS.202005-558OC","article-title":"Validation of a prediction score for drug-resistant microorganisms in community-acquired pneumonia","volume":"18","author":"A Ceccato","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1513\/AnnalsATS.202009-1207ED","article-title":"Community-acquired pneumonia owing to multidrug-resistant pathogens: a step toward an early identification","volume":"18","author":"M Falcone","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.03071-15","article-title":"Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score","volume":"60","author":"B J Webb","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1164\/rccm.202109-2092OC","article-title":"A pragmatic, stepped-wedge, cluster-controlled clinical trial of real-time pneumonia clinical decision support","volume":"205","author":"N C Dean","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jhm.942","article-title":"Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia","volume":"7","author":"K J Madaras-Kelly","year":"2012","journal-title":"J Hosp Med"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/arm91030018","article-title":"Identify drug-resistant pathogens in patients with community-acquired pneumonia","volume":"91","author":"F Amati","year":"2023","journal-title":"Adv Respir Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e79014","DOI":"10.7554\/eLife.79014","article-title":"Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial","volume":"11","author":"Y Wang","year":"2022","journal-title":"eLife"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-2600(22)00086-8","article-title":"Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial","volume":"10","author":"A M Darie","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13054-020-03114-y","article-title":"Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia","volume":"24","author":"C Monard","year":"2020","journal-title":"Crit Care"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"e00135-20","DOI":"10.1128\/JCM.00135-20","article-title":"Practical comparison of the BioFire FilmArray pneumonia panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections","volume":"58","author":"B W Buchan","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"e048187","DOI":"10.1136\/bmjopen-2020-048187","article-title":"Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units","volume":"11","author":"G Voiriot","year":"2021","journal-title":"BMJ Open"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"I Martin-Loeches","year":"2023","journal-title":"Intensive Care Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1136588","DOI":"10.3389\/fcimb.2023.1136588","article-title":"Microbiological diagnostic performance of metagenomic next-generation sequencing compared with conventional culture for patients with community-acquired pneumonia","volume":"13","author":"T Lin","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chest.2022.12.035","article-title":"Guideline-concordant antibiotic therapy for the hospital treatment of community-acquired pneumonia and 1-year all-cause and cardiovascular mortality in older adult patients surviving to discharge","volume":"163","author":"V F Corrales-Medina","year":"2023","journal-title":"Chest"},{"issue":"02","key":"ref43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","article-title":"New antibiotics for community-acquired pneumonia","volume":"32","author":"M H Kollef","year":"2019","journal-title":"Curr Opin Infect Dis"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"N S Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"S 03","key":"ref45","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"T M File Jr","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"S 03","key":"ref46","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"D E Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"S C Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"e01949-19","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with Community-Acquired Bacterial Pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"S McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17512433.2022.2100346","article-title":"A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia","volume":"15","author":"S G\u00f3mez-Zorrilla","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1378\/chest.09-2434","article-title":"Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia?","volume":"137","author":"M P Schreiber","year":"2010","journal-title":"Chest"},{"issue":"09","key":"ref51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.rmed.2012.04.003","article-title":"Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia","volume":"106","author":"S C Park","year":"2012","journal-title":"Respir Med"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.5588\/ijtld.12.0723","article-title":"Validation of a scoring tool to predict drug-resistant pathogens in hospitalised pneumonia patients","volume":"17","author":"S C Park","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/resp.12267","article-title":"Development and validation of a clinical risk score for predicting drug-resistant bacterial pneumonia in older Chinese patients","volume":"19","author":"H M Ma","year":"2014","journal-title":"Respirology"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jfma.2015.03.009","article-title":"Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens","volume":"115","author":"P H Wang","year":"2016","journal-title":"J Formos Med Assoc"},{"issue":"07","key":"ref55","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1017\/ice.2022.229","article-title":"Derivation and validation of a risk assessment model for drug-resistant pathogens in hospitalized patients with community-acquired pneumonia","volume":"44","author":"M B Rothberg","year":"2023","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1778138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:57:15Z","timestamp":1730804235000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1778138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":55,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1778138","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}